Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Bassanelli
MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Incidence, Risk Factors, and Impact on Survival of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Clinical Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology
Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer
Oncologist
Cancer Research
Medicine
Oncology
P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Association Between Adverse Events and Quality of Life in Patients Treated With Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Chemoradiotherapy Followed by Durvalumab in Patients With Unresectable Advanced Non‐small Cell Lung Cancer: Management of Adverse Events
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Nivolumab Improves Survival for Patients With Advanced Lung Cancer
Cancer
Cancer Research
Oncology
Predictive Factors Associated With Prolonged Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Gefitinib
British Journal of Cancer
Cancer Research
Oncology
